Amarillo Biosciences Warrant 2022-29.07.27 on Ainos AIMDW 深 沪
等待开盘 02-11 09:30:00 美东时间
0.1497
+0.038
+34.26%
华盛通- 最 高0.15
- 今 开0.15
- 成交量 2943股
- 最 低 0.14
- 昨 收 0.1115
- 总市值 0
- 52周最高 0.949
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.057
- 委 比 -95.77%
- 总股本 --
- 历史最高 0.949
- 量 比 0.55
- 振 幅 8.97%
- 历史最低 0.025
- 每 手 1
- 风险率 0.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ainos Collaborates With Mirle Automation To Integrate Ainos' AI Platform Into Robots, Quadruped Robots
Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced a technology partnership with Mirle
02-02 21:14
Ainos Secures Seven New Patents In Europe, Germany, Taiwan, And China, Enhancing Its AI Nose Digital Olfaction Platform For Robotics Applications
Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced it has secured seven new patents in Europe, Germany, Taiwan and China that strengthen its AI
2025-09-30 20:32
Ainos, Inc Announces Its Investigational Low-Dose Oral Interferon-Alpha Drug Candidate, Veldona Has Received Formal Approval From Taiwan's Food And Drug Administration To Initiate A Clinical Study For Primary Sjögren's Syndrome
Advancing a Novel, Side-Effect-Free Treatment for a Rare Yet Widely Underserved Autoimmune DiseaseAinos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Texas incorporated, dual-platform AI and biotech
2025-08-04 20:04
Ainos Regains Nasdaq Compliance, Accelerates AI Nose Platform Commercialization With 90-Day Execution Plan
Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization, today announced it has regained compliance with the minimum bid price requirement for continued listing on
2025-07-16 20:09
Ainos To Implement Consolidation Of Its Common Stock, Effective June 30, 2025
Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it will implement a consolidation of its common stock ("stock consolidation"), effective at the opening of trading on June 30, 2025.
2025-06-26 23:02
Ainos, Inc. Announces 1-For-5 Stock Consolidation
Ainos, Inc. (NASDAQ:AIMD, AIMDW)))) ("Ainos," or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, VELDONA® low-dose interferon therapeutics, and
2023-12-12 21:03
Ainos Announces Successful Manufacturing Of VELDONA GMP Clinical Batch By Swiss Pharmaceutical
Subsequent Phase Involves Completion of Chemistry, Manufacturing, and Controls (CMC) InformationAinos Intends to Submit Investigational New Drug Applications to the U.S. FDA for Multiple Candidates During the First Half
2023-11-28 21:41
Ainos Announces Placement Of Initial $3M Tranche Of $10M Private Placement; Proceeds To Fund Company's Clinical Trials, Commercial Product Launch, And Working Capital; Initial Conversion Price Set At $1.50 Per Share
Proceeds to fund company's clinical trials, commercial product launch, and working capitalInitial conversion price set at $1.50 per shareSAN DIEGO, CA / ACCESSWIRE / September 25, 2023 / Ainos, Inc. (NASDAQ:AIMD,
2023-09-25 20:33
